Currently out of the existing stock ratings of Joseph Pantginis, 789 are a BUY (96.57%), 27 are a HOLD (3.3%), 1 are a SELL (0.12%).

Joseph Pantginis

Work Performance Price Targets & Ratings Chart

Analyst Joseph Pantginis, carries an average stock price target met ratio of 40.17% that have a potential upside of 45.78% achieved within 241 days. Previously, Joseph Pantginis worked at HC WAINWRIGHT.

Joseph Pantginis’s has documented 1,465 price targets and ratings displayed on 69 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PDSB, PDS Biotechnology Corp at 07-Mar-2025.

Wall Street Analyst Joseph Pantginis

Analyst best performing recommendations are on PROG (PROGENITY).
The best stock recommendation documented was for BCDA (BIOCARDIA ) at 8/16/2024. The price target of $4 was fulfilled within 3 days with a profit of $0.68 (20.48%) receiving and performance score of 68.27.

Average potential price target upside

of $98.2 (65%) on CRIS (CURIS).
of $88.76 (25.06%) on REGN (REGENERON PHARMACEUTICALS).
of $79.96 (73.35%) on VSTM (VERASTEM).

ADRO Aduro Biotech ATNM Actinium Pharmaceuticals CAPR Capricor Therapeutics CLBS Caladrius Biosciences LCTX Lineage Cell Therapeutics PTN Palatin Technologies REGN Regeneron Pharmaceuticals SSKN STRATA Skin Sciences XBIO Xenetic Biosciences AGTC Applied Genetic CYTK Cytokinetics LGND Ligand Pharmaceuticals VSTM Verastem APTO Aptose Biosciences CLDX Celldex Therapeutics DBTX Decibel Therapeutics IOVA Iovance Biotherapeutics KRYS Krystal Biotech KURA Kura Oncology LIFE aTyr Pharma PHGE Biomx PROG Progenity RIGL Rigel Pharmaceuticals BCDA Biocardia BYSI BeyondSpring KDNY Chinook Therapeutics SIOX Sio Gene Therapies VYNE Vyne Therapeutics XOMA XOMA Corp CLNN Clene CMPX Compass Therapeutics BMEA Biomea Fusion CKPT Checkpoint Therapeutics IMV IMV ARAV Aravive ARMP Armata Pharmaceuticals ATXS Astria Therapeutics BCEL Atreca BNOX Bionomics Ltd ADR BPTS Biophytis ESPR Esperion Therapeutics GNTA Genenta Science SpA ADR MDGL Madrigal Pharmaceuticals NVCT Nuvectis Pharma PDSB PDS Biotechnology Corp STTK Shattuck Labs TNYA Tenaya Therapeutics TPST Tempest Therapeutics SNSS Sunesis Pharmaceuticals TGTX TG Therapeutics ALPN Alpine Immune Sciences APRE Aprea Therapeutics BLRX BioLineRx Ltd MBIO Mustang Bio ONTX Onconova Therapeutics PBLA Panbela Therapeutics VKTX Viking Therapeutics AKUS Akouos CDMO Avid Bioservices CNCE Concert Pharmaceuticals CRIS Curis PRNB Principia Biopharma PSTV Plus Therapeutics GNCA Genocea Biosciences SPHS Sophiris Bio SRRA Sierra Oncology STML Stemline Therapeutics VBLT Vascular Biogenics Ltd LXRX Lexicon Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Joseph Pantginis (HC WAINWRIGHT)

Hold

$18.75

$4.15 (28.42%)

$100

4 years 9 months 9 days ago
(02-Jun-2020)

0/8 (0%)

$5.9 (45.91%)

Please subscribe to see the analyst performance score

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Joseph Pantginis is most bullish on?

Potential upside of $82.18 has been obtained for XOMA (XOMA CORP)

Which stock is Joseph Pantginis is most reserved on?

Potential downside of -$0 has been obtained for XBIO (XENETIC BIOSCIENCES)

What Year was the first public recommendation made by Joseph Pantginis?

On 2010